Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(17%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
33%
Ph phase_4
1
17%
Ph phase_1
1
17%
Ph phase_3
2
33%

Phase Distribution

1

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Other(1)

Detailed Status

Completed4
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 22 (33.3%)
Phase 32 (33.3%)
Phase 41 (16.7%)

Trials by Status

unknown117%
recruiting117%
completed467%

Recent Activity

1 active trials
Showing 5 of 6
completedphase_2

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

NCT03244956
recruitingphase_2

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

NCT05668962
completedphase_3

Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal

NCT04971473
unknownphase_3

Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer

NCT04964284
completedphase_1

Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123

NCT02278198
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03244956Phase 2

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

Completed
NCT05668962Phase 2

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Recruiting
NCT04971473Phase 3

Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal

Completed
NCT04964284Phase 3

Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer

Unknown
NCT02278198Phase 1

Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123

Completed
NCT00604318Phase 4

Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6